Evobrutinib

Last updated

Evobrutinib
Evobrutinib.svg
Legal status
Legal status
  • Investigational
Identifiers
  • 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C25H27N5O2
Molar mass 429.524 g·mol−1
3D model (JSmol)
  • C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
  • InChI=InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
  • Key:QUIWHXQETADMGN-UHFFFAOYSA-N

Evobrutinib is an experimental drug being studied for the treatment of encephalomyelitis and multiple sclerosis. [1] [2] [3] It is an inhibitor of Bruton's tyrosine kinase. [4]

References

  1. ↑ "Evobrutinib". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, et al. (April 2024). "Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study". Multiple Sclerosis. 30 (4–5): 558–570. doi:10.1177/13524585241234783. PMC   11080380 . PMID   38436271.
  3. ↑ Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross AH, et al. (November 2024). "Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials". The Lancet. Neurology. 23 (11): 1119–1132. doi:10.1016/S1474-4422(24)00328-4. PMID   39307151.
  4. ↑ "Evobrutinib". Multiple Sclerosis Trust.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.